Neuroptika’s mission is to improve patients’ lives by developing novel regenerative therapies for ophthalmic diseases
NRO-1
A POTENTIAL DISEASE MODIFYING TREATMENT
Neuroptika is leveraging insights into the relationship between nerve degeneration and ophthalmic diseases to develop transformative treatments.
​
NRO-1, Neuroptika's lead therapy, is a nerve regenerative therapeutic that can treat the underlying cause of degenerative ophthalmic diseases.
Corneal Nerve Degeneration
Retinal Ganglion Cell Degeneration
Â
NRO-1 PROGRAMS
NRO-1 has successfully completed a Phase 1 study. A Phase 2 study for dry eye disease is ongoing.
Â
Functional Benefits of NRO-1
Â
Â